




RealRate

# PHARMACEUTICAL 2016

Theravance Biopharma Inc  
Rank 127 of 295

Theravance  
Biopharma  
Medicines That Make a Difference



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Theravance Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Theravance Biopharma Inc is the variable Net Income, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 308%, being 45% points above the market average of 263%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 237,472              |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 49,470               |
| Liabilities, Non-Current                    | 0                    |
| Other Assets                                | 52,771               |
| Other Compr. Net Income                     | 12                   |
| Other Expenses                              | 5,608                |
| Other Liabilities                           | 0                    |
| Other Net Income                            | 631                  |
| Other Revenues                              | 42,126               |
| Property and Equipment                      | 9,873                |
| Research and Development                    | 129,165              |
| Selling, General and Administrative Expense | 90,203               |

| Output Variable              | Value in<br>1000 USD |
|------------------------------|----------------------|
| Assets                       | 300,116              |
| Liabilities                  | 49,470               |
| Expenses                     | 224,976              |
| Revenues                     | 42,126               |
| Stockholders Equity          | 250,646              |
| Net Income                   | -182,219             |
| Comprehensive Net Income     | -182,213             |
| BaseVar                      | 308,666              |
| ECR before Limited Liability | 208%                 |
| Economic Capital Ratio       | 308%                 |